Abstract
Today, there are more than 32 million patients with diabetes in the Middle East (ME), the number is expected to double by 2040. In contrast to Europe and North America and despite the high prevalence of diabetes in ME, epidemiological data about incident and types of diabetes in the region is very limited.
Maturity-onset diabetes of the young (MODY) is a subtype of monogenic diabetes representing 2-5% of all diabetes patients. The disease is autosomal dominant mode of inheritance characterized by β-cell malfunction below the age of 35 years. To date, there are 15 different MODY forms that have been identified; each has a distinct genetic etiology.
It is very common that MODY is misdiagnosed between with type 1 or type 2 diabetes. Hence, accurate genetic diagnosis is crucial to individualize the treatment and to improve glycaemia control. New technologies such as next-generation sequencing (NGS) offer an excellent alternative to screen and identify causative MODY mutations. In this review, we summarize the main clinical and genetic characteristics for each MODY form. In addition, we shed light on MODY studies that have been executed in the ME region.
Keywords: Maturity-onset diabetes of the young, Middle East, monogenic diabetes, autosomal dominant mode, glycaemia, next-generation sequencing.
Current Molecular Medicine
Title:Maturity-Onset Diabetes of the Young: An Overview with Focus on the Middle East
Volume: 17 Issue: 8
Author(s): J. Taneera*, B. Mussa, M. Saber-Ayad, S. Dhaiban, H. Aljaibeji and N. Sulaiman
Affiliation:
- University of Sharjah, College of Medicine, Sharjah Institute for Medical Research, Sharjah,United Arab Emirates
Keywords: Maturity-onset diabetes of the young, Middle East, monogenic diabetes, autosomal dominant mode, glycaemia, next-generation sequencing.
Abstract: Today, there are more than 32 million patients with diabetes in the Middle East (ME), the number is expected to double by 2040. In contrast to Europe and North America and despite the high prevalence of diabetes in ME, epidemiological data about incident and types of diabetes in the region is very limited.
Maturity-onset diabetes of the young (MODY) is a subtype of monogenic diabetes representing 2-5% of all diabetes patients. The disease is autosomal dominant mode of inheritance characterized by β-cell malfunction below the age of 35 years. To date, there are 15 different MODY forms that have been identified; each has a distinct genetic etiology.
It is very common that MODY is misdiagnosed between with type 1 or type 2 diabetes. Hence, accurate genetic diagnosis is crucial to individualize the treatment and to improve glycaemia control. New technologies such as next-generation sequencing (NGS) offer an excellent alternative to screen and identify causative MODY mutations. In this review, we summarize the main clinical and genetic characteristics for each MODY form. In addition, we shed light on MODY studies that have been executed in the ME region.
Export Options
About this article
Cite this article as:
Taneera J. *, Mussa B. , Saber-Ayad M. , Dhaiban S. , Aljaibeji H. and Sulaiman N. , Maturity-Onset Diabetes of the Young: An Overview with Focus on the Middle East, Current Molecular Medicine 2017; 17 (8) . https://dx.doi.org/10.2174/1566524018666180222121158
DOI https://dx.doi.org/10.2174/1566524018666180222121158 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Current Diabetes Reviews Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
CNS & Neurological Disorders - Drug Targets Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Current Bioactive Compounds Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Lipid Disorders in Diabetes Mellitus and Current Management
Current Pharmaceutical Analysis Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Ultra-Fast Acting Insulin Analogues
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Pills of Emergency Medicine: Deal or Not Deal?
Reviews on Recent Clinical Trials Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
Current Drug Safety Dietary Management of Gestational Diabetes Mellitus
Current Nutrition & Food Science Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews